kalkinemedia7h
How Eli Lilly (NYSE:LLY) Is Expanding Its Pharmaceutical Leadership
Highlights,Eli Lilly achieved a 20.4% revenue growth year-over-year in Q3.,Earnings per share (EPS) fell below expectations ...
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Eli Lilly & Co: Buy Rating Backed by Promising Orfoglipron Trials and Strong Pharmaceutical Pipeline
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Argus Research Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Argus Research analyst Jasper Hellweg maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares ...
My Top 5 Stocks to Buy in Early 2025
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...
Viking Therapeutics: Investors Meeting Reality Of The Obesity Market
Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.
STAT19h
RFK Jr. to face key Senate committee hearings next week
The Senate Finance Committee hearing on the nomination will be on Jan. 29, per an announcement obtained by STAT. The Senate ...